A5083493206- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Peptidase Inhibition and Analysis
- Head and Neck Cancer Studies
- Sarcoma Diagnosis and Treatment
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- Economic and Financial Impacts of Cancer
- Cancer Cells and Metastasis
- Metastasis and carcinoma case studies
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Apelin-related biomedical research
- Brain Metastases and Treatment
- Sepsis Diagnosis and Treatment
- Lipid metabolism and disorders
- Advanced Breast Cancer Therapies
- Ultrasound in Clinical Applications
Cliniques Universitaires Saint-Luc
2015-2025
UCLouvain
2015-2024
de Duve Institute
2016-2022
Hôpital de Jolimont
2014-2017
Clinique Saint-Joseph
2013-2014
To evaluate the efficacy and safety of tucatinib trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) metastatic biliary tract cancer (mBTC).
The phase 2 TROPiCS-03 study evaluated the efficacy/safety of sacituzumab govitecan (SG) as second-line treatment in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC).
Forty to fifty percent of patients with locally advanced squamous cell carcinoma the head and neck (LA SCCHN) relapse despite multimodal treatment. Circulating tumor DNA (ctDNA) has potential detect minimal residual disease (MRD) after curative-intent therapy identify earlier which will progress. We developed a tumor-agnostic plasma ctDNA assay MRD in unselected LA SCCHN aim predicting progression-free survival (PFS) overall without need for sequencing.A 26-gene next-generation sequencing...
Abstract Background Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early-stage triple negative breast cancers (TNBC). However, more than half TNBC do not achieve a pathological complete response (pCR) after NAC, and residual cancer burden (RCB) associated dismal long-term prognosis. Understanding mechanisms underlying differential treatment outcomes therefore critical to limit RCB improve NAC efficiency. Methods Human cell lines patient-derived organoids were used...
Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) signaling promotes cell and differentiation, is overexpressed in several tumor types, including breast, gastric colorectal cancer. HER2-targeted therapies have shown clinical activity against these resulting regulatory approvals. However, the efficacy of HER2 tumors with mutations has not been widely investigated. SGNTUC-019 an open-label, phase basket study evaluating tucatinib, a tyrosine kinase inhibitor, combination...
Anti-epidermal growth factor receptor (EGFR) therapy (cetuximab) shows a limited clinical benefit for patients with locally advanced or recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), due to the frequent occurrence of secondary resistance mechanisms. Here we report that cetuximab-resistant HNSCC cells display peroxisome proliferator-activated alpha (PPARα)-mediated lipid metabolism reprogramming, increased fatty acid uptake oxidation capacities, while glycolysis is not...
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) play a central role in early‐stage breast cancer (BC) are associated with chemoresistance, stemness, invasion. The objective of this study was two fold: (a) by investigating the predictive value EMT TILs, we aimed to estimate chance achieving response after neoadjuvant chemotherapy (NAC) (b) evaluate potential changes TILs BC upon NAC. Using bulk RNA sequencing immunofluorescence (IF) for (E‐cadherin vimentin)...
Abstract The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making patients with advanced cancers. This multi-center enrolled 872 from 12 hospitals. CGP was performed on tumor tissues a standardized panel (523 genes) across nine laboratories success 93% and median turnaround time 29 days. Actionable markers were identified 81% patients, substantially higher than 21%...
Patients with HER2-positive invasive breast cancer that is node-positive and/or larger than 3 cm are generally treated neoadjuvant chemotherapy (NAC). We aimed to identify predictive markers for pathological complete response (pCR) after NAC in carcinoma.
The identification of gene fusions has become an integral part soft tissue and bone tumour diagnosis. We investigated the added value targeted RNA-based sequencing (targeted RNA-seq, Archer FusionPlex) to our current molecular diagnostic workflow these tumours, which is based on fluorescence in situ hybridisation (FISH) for detection using 25 probes. In a series 131 samples RNA-seq identified fusion, BCOR internal tandem duplication or ALK deletion 47 cases (35.9%). For 74 cases,...
Abstract Obesity is a known factor increasing the risk of developing breast cancer and reducing disease free survival. In addition to these well-documented effects, recent studies have shown that obesity also affecting response chemotherapy. Among multiple dysregulations associated with obesity, increased level apelin adipokine has been recently be directly involved in association between progression. this study, we analyzed retrospective cohort 62 patients impact tumoral expression on...
An early differential diagnosis is mandatory when facing a patient with clinical shock of unclear aetiology, in order to guide proper treatment. We assessed if the expired CO2 measurement and alveolar-arterial calculation could improve during its initial presentation, particularly separating pulmonary embolism from other causes shock. analysed charts 12 patients who presented had end-tidal (EtCO2) arterial partial pressure (PaCO2) measurements. In cases embolism-related (n = 3), gradient...
Tyrosine kinase inhibitors, represented by sunitinib, sorafenib, axitinib and pazopanib, are emerging molecules harbouring antitumoural efficacy in multiple neoplasia. We report the case of a 51-year-old woman with right thoracic sarcoma who developed fatal heart failure on pazopanib. The patient had no cardiovascular risk factor, except previous exposure to anthracycline, her cardiac function was normally controlled before initiating Despite rapid tumour response, fatigue rapidly appeared,...
•PRECISION is a national program involving academia, regulatory authorities, and the pharmaceutical industry.•It promotes molecular testing, data storage sharing, treatment access via trials tumor board.•The multistakeholder collaboration stepping stone to broader next-generation sequencing reimbursement for targeted therapies. PRECISION an initiative from Belgian Society of Medical Oncology (BSMO) in with several stakeholders, encompassing four programs that aim boost genomic clinical...